Browse Hematology/Oncology Articles by Topic

Sunvozertinib (Zegfrovy) Tablets

The U.S. Food and Drug Administration (FDA) has granted an accelerated approval to sunvozertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (EGFR exon20ins). The FDA also approved a companion diagnostic device, Oncomine Dx Express Test to help detect exon20ins mutations.

Taletrectinib Capsules (Ibtrozi)

The U.S. Food and Drug Administration has approved a potent, selective, next-generation ROS Proto-Oncogene 1 (ROS1) receptor tyrosine kinase inhibitor, taletrectinib, for the treatment of ROS1-positive non-small cell lung cancer.

Avutometinib Capsules and Defactinib Tablets (Avmapki Fakzynja CO-PACK)

The U.S. Food and Drug Administration has granted accelerated approval for a combination of two kinase inhibitors, avutometinib and defactinib, for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, including a platinum-based regimen.

Telisotuzumab Vedotin-tlly (Emrelis)

The U.S. Food and Drug Administration has granted accelerated approval of telisotuzumab vedotin-tilly, a first-in-class c-mesenchymal-epithelial transition factor-directed antibody and a microtubule inhibitor conjugate for the treatment of locally advanced or metastatic, non-squamous non-small cell lung cancer.

Oncologic Emergencies

Oncologic emergencies cover a variety of conditions and complications that may occur in conjunction with malignancy. These include the initial presentations of new cancer diagnoses, complications of metastatic disease, and issues related to the adverse effects of treatment.

Pediatric Hematology/Oncology Trainees Want Ethics Expertise

Ethics education would not replace the option or need to obtain a formal ethics consultation. However, such education could lead to fewer cases during which specialists believe they need such assistance.

Physician Group Says to Start Colon Cancer Screening at Age 50 Years

Patient advocates push back, standing by other recommendations that set the age at 45 years.

Reconsidering Aspirin Therapy for Elderly Patients

A post-hoc analysis of the ASPREE trial revealed that in presumably healthy elderly subjects, taking low-dose aspirin daily over three years was associated with a significant drop in hemoglobin and ferritin levels vs. placebo, even when patients with major bleeding events were excluded.

Ethical Considerations When Using Gene-Editing Treatment for Sickle Cell Disease

Like any other treatment, it is important patients are aware of limitations, but without crushing their hopes that a cure might be feasible.

Advance Care Planning Can Lower Odds of Aggressive End-of-Life Treatment

Advance care planning was associated with significantly lower odds of indicators of aggressive end-of-life care (i.e., hospital death, hospital admissions, intensive care, delayed hospice referrals, and chemotherapy). Cancer patients who engaged in advance care planning were 50% more likely to complete Do Not Resuscitate orders compared to cancer patients without an advance directive.